Huang Sheng-Chieh, Chang Shih-Ching, Jiang Jeng-Kai, Su Yi-Tien
Faculty of Medicine, School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.
Division of Colorectal Surgery, Department of Surgery, Taipei Veterans General Hospital, Taipei, Taiwan.
Int J Colorectal Dis. 2025 Jul 2;40(1):150. doi: 10.1007/s00384-025-04943-5.
This study aims to evaluate the prognostic influence of different metastatic sites and the effect of surgical resection on survival. Additionally, it explores how anatomical location influences prognosis before and after metastasectomy.
This retrospective study included 999 mCRC patients treated at Taipei Veterans General Hospital from 2013 to 2019. Survival outcomes across liver, lung, peritoneal, and distant lymph node (LN) metastases were analyzed using Kaplan-Meier and Cox regression models.
Prognosis varied significantly by metastatic site. For single-site metastases, distant LN metastases had the longest OS (36.8 months), followed by lung (35.5 months), liver (26.5 months), and peritoneal metastases (21.5 months; p = 0.001). Lung metastases showed the longest PFS (11.7 months), followed by distant LN (10.8 months), peritoneal (9.8 months), and liver (9.1 months; p = 0.031). Surgical resection significantly improved OS (HR = 0.477, p < 0.001). With metastasectomy, OS was comparable for liver, lung, and distant LN metastases (p = 0.288), while peritoneal metastases had significantly poorer outcomes (HR = 2.208, p = 0.001). In patients without surgery, OS was significantly poorer across all metastatic sites, with lung metastases demonstrating the most favorable prognosis (OS = 31.9 months) and statistically significant differences compared to liver, peritoneal, and distant LN metastases (p < 0.001).
The prognosis of mCRC varies by metastatic site. Surgical resection significantly improves survival for liver, lung, and distant LN metastases but is less effective for peritoneal metastases. Surgery reduces the prognostic disparity among resectable sites except for peritoneal seeding.
本研究旨在评估不同转移部位的预后影响以及手术切除对生存的影响。此外,还探讨了解剖位置如何影响转移灶切除术前和术后的预后。
这项回顾性研究纳入了2013年至2019年在台北荣民总医院接受治疗的999例mCRC患者。使用Kaplan-Meier和Cox回归模型分析了肝、肺、腹膜和远处淋巴结(LN)转移患者的生存结果。
预后因转移部位而异。对于单部位转移,远处LN转移的总生存期最长(36.8个月),其次是肺(35.5个月)、肝(26.5个月)和腹膜转移(21.5个月;p = 0.001)。肺转移的无进展生存期最长(11.7个月),其次是远处LN(10.8个月)、腹膜(9.8个月)和肝(9.1个月;p = 0.031)。手术切除显著改善了总生存期(HR = 0.477,p < 0.001)。进行转移灶切除术后,肝、肺和远处LN转移的总生存期相当(p = 0.288),而腹膜转移的预后明显较差(HR = 2.208,p = 0.001)。在未接受手术的患者中,所有转移部位的总生存期均明显较差,肺转移的预后最有利(总生存期 = 31.9个月),与肝、腹膜和远处LN转移相比有统计学显著差异(p < 0.001)。
mCRC的预后因转移部位而异。手术切除显著提高了肝、肺和远处LN转移患者的生存率,但对腹膜转移的效果较差。手术减少了可切除部位(除腹膜种植外)之间的预后差异。